Neuphoria Therapeutics Inc.

For the period ended Jun 30, 2026. Filed Sep 18, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2026 · Filed Sep 18, 2026

NEUP$2.69-2.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations and Other Comprehensive Income (Loss)

	Year Ended June 30,
2026 · 2025
Revenue
License revenue	$	-	$15,649,448
Collaborative arrangement revenue		1,174,165	-
Total revenue		1,174,165	15,649,448
Operating expenses
Research and development		3,545,421	9,005,097
General and administrative		7,439,224	7,773,442
Restructuring costs		1,278,586	-
Goodwill impairment		5,362,000	-
Total operating expenses		17,625,231	16,778,539
Loss from operations		(16,451,066)	(1,129,091)
Other income (loss)
Interest income, net		665,571	166,498
Loss on foreign currency transactions		(535,722)	(414,996)
Research and development incentive award		800,904	299,905
Gain on fair value adjustments		1,929,209	239,686
Total other income		2,859,962	291,093
Loss before income taxes		(13,591,104)	(837,998)
Income tax benefit		139,173	468,366
Net loss		(13,451,931)	(369,632)
Other comprehensive income
Unrealized gain on foreign currency translation		781,896	168,529
Total other comprehensive income		781,896	168,529
Comprehensive loss		$(12,670,035)	$(201,103)
Net loss per share - basic and diluted		$(3.06)	$(0.23)
Weighted-average common shares outstanding - basic and diluted		4,395,776	1,622,924

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.